The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices

Growing revenues from Casgevy will help CRISPR Therapeutics fund the development of its pipeline therapies. The gene-editing biotech isn't profitable yet.

The Motley Fool • Feb 20, 2026

Is CRISPR Therapeutics Stock Going to $0, or Will the Hype Pay Off?

CRISPR Therapeutics has some promising and innovative pipeline candidates. The stock will soar if it can execute and deliver strong clinical and regulatory progress.

The Motley Fool • Feb 20, 2026

CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows

CRISPR Therapeutics AG NASDAQ: CRSP stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that may seem contradictory.

MarketBeat • Feb 19, 2026

2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street

Biotech companies could add growth to your portfolio -- and in some cases, at a bargain price. It's a great idea to select tomorrow's potential winners and hold on as their stories unfold.

The Motley Fool • Feb 19, 2026

Should You Buy Shares of CRISPR Therapeutics in February?

Casgevy is starting to build some serious sales momentum. CRISPR Therapeutics also has a deep pipeline and healthy funding.

The Motley Fool • Feb 18, 2026

CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Seeking Alpha • Feb 18, 2026

Crispr Therapeutics: Very High Risk But Even Higher Potential Reward

CRISPR Therapeutics is rated 'Buy' for its blockbuster CASGEVY launch, robust cash position, and high upside despite significant risks. CASGEVY's gene-editing therapy targets severe SCD and TDT, with modeled 2030 peak sales of $5.8B and orphan exclusivity until 2031. DCF-based fair value is $91.95, implying 73% upside with 57% revenue CAGR 2026-2035, but more conservative scenarios suggest CRSP might be fairly valued.

Seeking Alpha • Feb 19, 2026

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Investment Research • Feb 17, 2026

CRISPR Therapeutics Q4: The Elite Time To Buy Is In 2027

CRISPR Therapeutics AG is commercially validated with CASGEVY but remains financially unproven and operates at a loss despite strong cash reserves. Incremental buying is attractive now for patient CRSP investors, with major upside expected as revenue scales and normalized EPS turns positive, likely post-2027. The 60/40 global profit split with Vertex offers operating leverage, positioning CRSP for free cash flow as adoption and execution improve.

Seeking Alpha • Feb 17, 2026

Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss)

CRISPR Therapeutics' fourth quarter was relatively disappointing. As a biotech start-up still in its infancy though, these early quarterly numbers don't mean much.

The Motley Fool • Feb 13, 2026